EPHX2 and early-onset autosomal dominant Alzheimer disease: Inhibition of sEH, the enzyme largely responsible for the degradation of CYP PUFA metabolites, has been shown to be beneficial in Alzheimer’s disease (AD) and Parkinson’s disease (PD) [18].